17:21 EDT Regenxbio (RGNX) files to sell 268,096 shares of common stock for holders
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism
- Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio’s RGX-202
- RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating
- Regenxbio’s RGX-202 shows efficacy in Phase 1/2 Duchenne trial
- RegenXBio Holds 2025 Annual Stockholders Meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue